title: Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis.
authors.affiliation: Department of Dermatology, Warsaw Medical School, Poland.
authors.forename: L
authors.initials: L
authors.lastname: Rudnicka
authors.forename: J
authors.initials: J
authors.lastname: Czuwara
authors.forename: A
authors.initials: A
authors.lastname: Barusińska
authors.forename: U
authors.initials: U
authors.lastname: Nowicka
authors.forename: B
authors.initials: B
authors.lastname: Makieła
authors.forename: S
authors.initials: S
authors.lastname: Jabłonska
mesh_terms: D002166:Camptothecin / Q000627:therapeutic use*; D003094:Collagen / Q000096:biosynthesis; D004264:DNA Topoisomerases, Type I / Q000096:biosynthesis; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000201:enzymology; D012867:Skin / Q000187:drug effects / Q000201:enzymology; D059004:Topoisomerase I Inhibitors
chemical_list: D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D059004:Topoisomerase I Inhibitors; D003094:Collagen; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin